CoChat
Sign Up
Cited by 41

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation

Laubach, Jacob P., Fu, Ping, Jiang, Xiaohong, Salter, Kelly H., Potti, Anil, Arcasoy, Murat O.·2009·Experimental Hematology
DOI 10.1016/j.exphem.2009.09.009PMC PMC2783925
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.exphem.2009.09.009

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 51

  1. Prchal, 1974, Letter: Bone-marrow responses in polycythemia vera, N Engl J Med, 290, 1382, 10.1056/NEJM197406132902419 · DOI
  2. Eaves, 1978, Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera, Blood, 52, 1196, 10.1182/blood.V52.6.1196.1196 · DOI
  3. Casadevall, 1982, Erythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures, Blood, 59, 447, 10.1182/blood.V59.2.447.447 · DOI
  4. Means, 1989, Erythropoietin receptors in polycythemia vera, J Clin Invest, 84, 1340, 10.1172/JCI114303 · DOI
  5. Hess, 1994, Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera, Br J Haematol, 88, 794, 10.1111/j.1365-2141.1994.tb05119.x · DOI
  6. James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, 434, 1144, 10.1038/nature03546 · DOI
  7. Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023 · DOI · Paper page
  8. Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders, N Engl J Med, 352, 1779, 10.1056/NEJMoa051113 · DOI · Paper page
  9. Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Lancet, 365, 1054, 10.1016/S0140-6736(05)74230-6 · DOI · Paper page
  10. Zhao, 2005, Identification of an acquired JAK2 mutation in polycythemia vera, J Biol Chem, 280, 22788, 10.1074/jbc.C500138200 · DOI
  11. Wernig, 2006, Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model, Blood, 107, 4274, 10.1182/blood-2005-12-4824 · DOI
  12. Bumm, 2006, Characterization of murine JAK2V617F-positive myeloproliferative disease, Cancer Res, 66, 11156, 10.1158/0008-5472.CAN-06-2210 · DOI
  13. Lacout, 2006, JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis, Blood, 108, 1652, 10.1182/blood-2006-02-002030 · DOI
  14. Zaleskas, 2006, Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F, PLoS ONE, 1, e18, 10.1371/journal.pone.0000018 · DOI
  15. Tiedt, 2008, Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice, Blood, 111, 3931, 10.1182/blood-2007-08-107748 · DOI
  16. Shide, 2008, Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F, Leukemia, 22, 87, 10.1038/sj.leu.2405043 · DOI
  17. Rumi, 2006, JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders, Cancer, 107, 2206, 10.1002/cncr.22240 · DOI
  18. Bellanne-Chantelot, 2006, Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders, Blood, 108, 346, 10.1182/blood-2005-12-4852 · DOI
  19. Nussenzveig, 2007, Polycythemia vera is not initiated by JAK2V617F mutation, Exp Hematol, 35, 32, 10.1016/j.exphem.2006.11.012 · DOI
  20. Kralovics, 2006, Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders, Blood, 108, 1377, 10.1182/blood-2005-11-009605 · DOI
  21. Parganas, 1998, Jak2 is essential for signaling through a variety of cytokine receptors, Cell, 93, 385, 10.1016/S0092-8674(00)81167-8 · DOI
  22. Witthuhn, 1993, JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin, Cell, 74, 227, 10.1016/0092-8674(93)90414-L · DOI
  23. Feng, 1997, Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop, Mol Cell Biol, 17, 2497, 10.1128/MCB.17.5.2497 · DOI
  24. Richmond, 2005, Turning cells red: signal transduction mediated by erythropoietin, Trends Cell Biol, 15, 146, 10.1016/j.tcb.2005.01.007 · DOI
  25. Klingmuller, 1995, Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals, Cell, 80, 729, 10.1016/0092-8674(95)90351-8 · DOI
  26. Sokol, 1995, Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin, Blood, 86, 15, 10.1182/blood.V86.1.15.bloodjournal86115 · DOI
  27. Arcasoy, 1999, A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation, Exp Hematol, 27, 63, 10.1016/S0301-472X(98)00003-4 · DOI
  28. Watowich, 1999, Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state, Blood, 94, 2530, 10.1182/blood.V94.7.2530.419k35_2530_2532 · DOI
  29. Socolovsky, 1999, Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction, Cell, 98, 181, 10.1016/S0092-8674(00)81013-2 · DOI
  30. Socolovsky, 2001, Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts, Blood, 98, 3261, 10.1182/blood.V98.12.3261 · DOI
  31. Garcon, 2006, Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells, Blood, 108, 1551, 10.1182/blood-2005-10-009514 · DOI
  32. Grebien, 2008, Stat5 activation enables erythropoiesis in the absence of EPOR and Jak2, Blood, 111, 4511, 10.1182/blood-2007-07-102848 · DOI
  33. Zhang, 2004, Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors, Blood, 104, 1679, 10.1182/blood-2004-04-1362 · DOI
  34. Menon, 2006, Core erythropoietin receptor signals for late erythroblast development, Blood, 107, 2662, 10.1182/blood-2005-02-0684 · DOI
  35. Klingmuller, 1997, Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors, Proc Natl Acad Sci U S A, 94, 3016, 10.1073/pnas.94.7.3016 · DOI
  36. Ghaffari, 2006, AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation, Blood, 107, 1888, 10.1182/blood-2005-06-2304 · DOI
  37. Arcasoy, 2005, Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor, Br J Haematol, 130, 121, 10.1111/j.1365-2141.2005.05580.x · DOI
  38. Panzenbock, 1998, Growth and differentiation of human stem cell factor/erythropoietin-dependent erythroid progenitor cells in vitro, Blood, 92, 3658, 10.1182/blood.V92.10.3658 · DOI
  39. Bild, 2006, Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature, 439, 353, 10.1038/nature04296 · DOI
  40. Potti, 2006, Genomic signatures to guide the use of chemotherapeutics, Nat Med, 12, 1294, 10.1038/nm1491 · DOI
  41. Anders, 2008, Age-specific differences in oncogenic pathway deregulation seen in human breast tumors, PLoS ONE, 3, e1373, 10.1371/journal.pone.0001373 · DOI
  42. Montagna, 1994, In vitro sensitivity of human erythroid progenitors to hemopoietic growth factors: studies on primary and secondary polycythemia, Haematologica, 79, 311
  43. Dupont, 2007, The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera, Blood, 110, 1013, 10.1182/blood-2006-10-054940 · DOI
  44. Somervaille, 2001, Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax, Blood, 98, 1374, 10.1182/blood.V98.5.1374 · DOI
  45. Gaikwad, 2007, In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele, Exp Hematol, 35, 587, 10.1016/j.exphem.2006.12.007 · DOI
  46. Zeuner, 2006, Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells, Blood, 107, 3495, 10.1182/blood-2005-07-3037 · DOI
  47. Schmidt, 2004, PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors, BMC Biol, 2, 7, 10.1186/1741-7007-2-7 · DOI
  48. Halupa, 2005, Erythropoietin receptor Y479 couples to ERK1/2 activation via recruitment of phospholipase Cgamma, Exp Cell Res, 309, 1, 10.1016/j.yexcr.2005.04.030 · DOI
  49. Verstovsek, 2008, WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation, Clin Cancer Res, 14, 788, 10.1158/1078-0432.CCR-07-0524 · DOI
  50. Dai, 2005, Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB, Exp Hematol, 33, 152, 10.1016/j.exphem.2004.10.017 · DOI
  51. Silva, 1998, Expression of Bcl-x in erythroid precursors from patients with polycythemia vera, N Engl J Med, 338, 564, 10.1056/NEJM199802263380902 · DOI

Cited by

See all 41

Metadata

Authors
Laubach, J. P., Fu, P., Jiang, X., Salter, K. H., Potti, A., & Arcasoy, M. O.
Venue
Experimental Hematology
Publisher
Elsevier BV
Published
2009-12
Volume
37
Issue
12
Pages
1411-1422
ISSN
0301-472X
DOI
10.1016/j.exphem.2009.09.009
PMC
PMC2783925
Cited by
41
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review